Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 17/20 | 0.91 |
| ▸ | ESR2 | Q92731 | 17/20 | 0.91 |
| ▸ | F2 | P00734 | 1/20 | 0.68 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.67 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.67 |
| ▸ | CNR1 | P21554 | 1/20 | 0.67 |
| ▸ | CNR2 | P34972 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4651558 | 1.00 | ESR1 (0.91) | ESR1ESR2F2ENPP3ENPP1 | |
| SCHEMBL4650742 | 0.95 | ESR1 (1.00) | ESR1ESR2F2ENPP3ENPP1 | |
| SCHEMBL6595006 | 0.95 | ESR1 (1.00) | ESR1ESR2F2ENPP3ENPP1 | |
| SCHEMBL7409821 | 0.94 | ESR1 (0.98) | ESR1ESR2F2ENPP3ENPP1 | |
| SCHEMBL4651940 | 0.94 | ESR1 (0.98) | ESR1ESR2F2ENPP3ENPP1 | |
| SCHEMBL7451884 | 0.92 | ESR1 (0.87) | ESR1ESR2F2CNR1 | |
| SCHEMBL7775840 | 0.92 | ESR1 (0.87) | ESR1ESR2F2CNR1 | |
| SCHEMBL7669007 | 0.91 | ESR1 (0.89) | ESR1ESR2ENPP3ENPP1CNR1 | |
| SCHEMBL6595743 | 0.90 | ESR1 (0.94) | ESR1ESR2F2CNR1 | |
| SCHEMBL6597972 | 0.90 | ESR1 (0.94) | ESR1ESR2F2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0895781-A2 | Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins | ELI LILLY AND COMPANY (US) | 1999-02-10 | — | — | EP | claimed |
| EP-0820769-A2 | Use of benzothiophenes for the manufacture of a medicament for the treatment of diseases associated with an excess of tachykinis | ELI LILLY AND COMPANY (US) | 1998-01-28 | — | — | EP | claimed |
| US-5663192-A | PSYCHOLOGICAL DISORDERS USING INDOLE, BENZOTHIOPHENE OR BENZOFURANS WITH AMINO AND ALKOXYBENZOYL GROUPS | ELI LILLY AND COMPANY (US) | 1997-09-02 | — | — | US | claimed |
| EP-0736007-A4 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-03-19 | — | — | EP | claimed |
| EP-0736007-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-10-09 | — | — | EP | claimed |
| EP-0716854-A2 | Compositions for inhibiting neuropeptide y receptors | ELI LILLY AND COMPANY (US) | 1996-06-19 | — | — | EP | claimed |
| WO-1996012489-A1 | BICYCLIC NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012488-A1 | BICYCLIC BRADYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-05-02 | — | — | WO | claimed |
| EP-0709090-A2 | Compositions for treating resistant tumors | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | claimed |
| WO-1996011677-A1 | METHODS FOR TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1996-04-25 | — | — | WO | claimed |
| EP-0707852-A2 | Bicyclic bradykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1995017382-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | claimed |
| EP-1093803-B1 | Cosmetic composition comprising an antagonist of the neuropeptide Y receptor | SANOFI AVENTIS (FR) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077333-A2 | USE OF A NEUROPEPTIDE Y ANTAGONIST FOR DAMAGED OR SENSITIVE LIPS | L'OREAL (FR) | 2007-07-12 | — | — | WO | disclosed |
| EP-0838217-B1 | Cosmetic composition containing neuropeptide Y receptor antagonist | SANOFI SYNTHELABO (FR) | 2003-01-15 | — | — | EP | disclosed |
| US-6313128-B1 | CAN BE USED AS LYPOLYSIS/LYPOGENESIS REGULATORS IN THE SKIN WITHOUT, INTERFERRING WITH THE SKIN'S NATURAL FUNCTIONS; FOR THERAPY OF SABORRHEA AND ACNE | SANOFI-SYNTHELABO (FR) | 2001-11-06 | — | — | US | disclosed |
| EP-1132463-A2 | Cosmetic composition comprising an antagonist of the neuropeptide Y receptor | SANOFI-SYNTHELABO (FR) | 2001-09-12 | — | — | EP | disclosed |
| EP-1093803-A2 | Cosmetic composition comprising antagonist of the neuropeptide Y receptor | SANOFI-SYNTHELABO (FR) | 2001-04-25 | — | — | EP | disclosed |
| US-6114336-A | Cosmetic composition containing a neuropeptide Y receptor antagonist | SANOFI (FR) | 2000-09-05 | — | — | US | disclosed |
| EP-0838217-A2 | Cosmetic composition containing neuropeptide Y receptor antagonist | SANOFI (FR) | 1998-04-29 | — | — | EP | disclosed |